Improved antitumor efficacy and reduced toxicity of liposomes containing bufadienolides

Archives of Pharmacal Research

Volumn 34, Issue 9, 2011, Pages 1487-1494

  Hu, Kaili ^a   Zhu, Lin ^b   Liang, Haiyuan ^a   Hu, Fuqiang ^c   Feng, Jianfang ^a  

^a SHANGHAI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

^b SHANGHAI INSTITUTE OF PHARMACEUTICAL INDUSTRY   (China)

^c ZHEJIANG UNIVERSITY   (China)

Author keywords

Antitumor; Bufadienolides; Liposomes; Long circulating; Poloxamers

Indexed keywords

BUFADIENOLIDE DERIVATIVE; LIPOSOME;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL KILLING; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; ENCAPSULATION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IN VITRO STUDY; IN VIVO STUDY; LD 50; LIPOSOMAL DELIVERY; LIVER CANCER; LUNG CANCER; MOUSE; NONHUMAN; PARTICLE SIZE; RAT; SUSTAINED DRUG RELEASE;

ANIMALS; ANTINEOPLASTIC AGENTS; BUFANOLIDES; CELL LINE, TUMOR; CELL SURVIVAL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG HYPERSENSITIVITY; DRUG STABILITY; FEMALE; GUINEA PIGS; HUMANS; LETHAL DOSE 50; LIPOSOMES; LIVER NEOPLASMS, EXPERIMENTAL; LUNG NEOPLASMS; MALE; MICE; MICE, INBRED STRAINS; MICROSCOPY, ELECTRON, TRANSMISSION; PARTICLE SIZE; RABBITS; RATS; RATS, SPRAGUE-DAWLEY; SURFACE PROPERTIES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 80755125538     PISSN: 02536269     EISSN: 19763786     Source Type: Journal    
DOI: 10.1007/s12272-011-0910-9     Document Type: Article

References (19)

1. S. G. Antimisiaris P. V. Ioannou P. M. Loiseau 2003 In-vitro antileishmanial and trypanocidal activities of arsonoliposomes and preliminary in-vivo distribution in BALB/c mice J. Pharm. Pharmacol. 55 647 652 12831507 10.1211/002235703765344559 1:CAS:528:DC%2BD3sXkvV2qsLs%3D (Pubitemid 36705575)
2. S. Batzri E. D. Korn 1973 Single bilayer liposomes prepared without sonication Biochim. Biophys. Acta 298 1015 1019 4738145 10.1016/0005-2736(73) 90408-2 1:CAS:528:DyaE3sXhsFGlu74%3D
3. G. H. Cheng 2001 Advances in quality determination, pharmacological studies and clinical application of toad venom Zhong Cao Yao 32 184 186 1:CAS:528:DC%2BD3MXitFymsr0%3D
4. R. P. Geyer 1967 Studies on the mechanism of intravenous fat emulsions Fette Med. 6 59 61
5. H. D. Han A. Lee C. K. Song T. Hwang H. Seong C. O. Lee B. C. Shin 2006 In vivo distribution and antitumor activity of heparin stabilized doxorubicin-loaded liposomes Int. J. Pharm. 313 181 188 16540270 10.1016/j.ijpharm.2006.02.007 1:CAS:528:DC%2BD28XjtVGqtbg%3D
6. S. Hashimoto Y. Jing N. Kawazoe Y. Masuda S. Nakajo T. Yoshida Y. Kuroiwa K. Nakaya 1997 Bufalin reduces the level of topoisomerase II in human leukemia cells and affects the cytotoxicity of anticancer drugs Leuk. Res. 21 875 883 9393603 10.1016/S0145-2126(97)00061-1 1:CAS:528:DyaK2sXns1Ogsrw%3D (Pubitemid 27488715)
7. R. Jeppsson S. Rossner 1975 The influence of emulsifying agents and of lipid soluble drugs on the fractional removal rate of lipid emulsions from the blood stream of the rabbit Acta Pharmacol. Toxicol (Copenh). 37 134 144 10.1111/j.1600-0773.1975.tb00830.x 1:CAS:528:DyaE2MXlsFahtbg%3D
8. Y. Kamano A. Yamashita T. Nogawa H. Morita K. Takeya H. Itokawa T. Segawa A. Yukita K. Saito M. Katsuyama G. R. Pettit 2002 QSAR evaluation of the Ch'an Su and related bufadienolides against the colchicine-resistant primary liver carcinoma cell line PLC/PRF/5(1) J. Med. Chem. 45 5440 5447 12459012 10.1021/jm0202066 1:CAS:528:DC%2BD38Xotlyhtrk%3D (Pubitemid 35424962)
9. J. S. Liu W. C. Ye 2009 Antitumor effects of venenum bufonis and its active components J. Int. Pharmaceut. Res. 36 115 120
10. Y. Malam M. Loizidou A. M. Seifalian 2009 Liposomes and nanoparticles: nanosized vehicles for drug delivery in cancer Trends Pharmacol. Sci. 30 592 599 19837467 10.1016/j.tips.2009.08.004 1:CAS:528:DC%2BD1MXhtlCku7zI
11. S. M. Moghimi A. C. Hunter J. C. Murray 2001 Long-circulating and target-specific nanoparticles: theory to practice Pharmacol. Rev. 53 283 318 11356986 1:CAS:528:DC%2BD3MXkt1Gnurc%3D (Pubitemid 32476118)
12. Y. M. Ning K. He R. Dagher R. Sridhara A. T. Farrell R. Justice R. Pazdur 2007 Liposomal doxorubicin in combination with bortezomib for relapsed or refractory multiple myeloma Oncology (Williston Park) 21 1503 1508 (Pubitemid 350247080)
13. D. Peer J. M. Karp S. Hong O. C. Farokhzad R. Margalit R. Langer 2007 Nanocarriers as an emerging platform for cancer therapy Nat. Nanotechnol. 2 751 760 18654426 10.1038/nnano.2007.387 1:CAS:528:DC%2BD2sXhtlyktL%2FI (Pubitemid 350223348)
14. S. D. Perrault C. Walkey T. Jennings H. C. Fischer W. C. Chan 2009 Mediating tumor targeting efficiency of nanoparticles through design Nano Lett. 9 1909 1915 19344179 10.1021/nl900031y 1:CAS:528:DC%2BD1MXktVejsr4%3D
15. A. Samad Y. Sultana M. Aqil 2007 Liposomal drug delivery systems: an update review Curr. Drug Deliv. 4 297 305 17979650 10.2174/156720107782151269 1:CAS:528:DC%2BD2sXhtFansb3M (Pubitemid 47554274)
16. Y. H. Su X. Q. Huang D. Z. Zhang Y. N. Zhang J. M. Xie C. Q. Linh 2003 HPLC separation and determination of bufadienolide in cinobufacini injection Zhong Cao Yao 25 24 27
17. J. T. Xie H. Wang A. S. Attele C. S. Yuan 2000 Effects of resibufogenin from toad venom on isolated Purkinje fibers Am. J. Chin. Med. 28 187 196 10999437 10.1142/S0192415X00000234 1:STN:280:DC%2BD3cvks1yltw%3D%3D
18. J. Y. Yeh W. J. Huang S. F. Kan P. S. Wang 2003 Effects of bufalin and cinobufagin on the proliferation of androgen dependent and independent prostate cancer cells Prostate 54 112 124 12497584 10.1002/pros.10172 1:CAS:528:DC%2BD3sXhtlShtL4%3D (Pubitemid 36120327)
19. P. Zagana M. Haikou P. Klepetsanis E. Giannopoulou P. V. Ioannou S. G. Antimisiaris 2008 In vivo distribution of arsonoliposomes: effect of vesicle lipid composition Int. J. Pharm. 347 86 92 17689900 10.1016/j.ijpharm.2007.06. 048 1:CAS:528:DC%2BD2sXhtlOjsrbN (Pubitemid 350180327)